- Home
- SLND vs CGEN Comparison
SLND vs CGEN Comparison
Compare SLND & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- CGEN
- Stock Information
- Founded
- SLND 1900
- CGEN 1993
- Country
- SLND United States
- CGEN Israel
- Employees
- SLND N/A
- CGEN N/A
- Industry
- SLND Military/Government/Technical
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLND Industrials
- CGEN Health Care
- Exchange
- SLND Nasdaq
- CGEN Nasdaq
- Market Cap
- SLND 175.8M
- CGEN 167.4M
- IPO Year
- SLND N/A
- CGEN 2000
- Fundamental
- Price
- SLND $4.49
- CGEN $1.80
- Analyst Decision
- SLND Strong Buy
- CGEN
- Analyst Count
- SLND 1
- CGEN 0
- Target Price
- SLND $5.00
- CGEN N/A
- AVG Volume (30 Days)
- SLND 72.5K
- CGEN 181.3K
- Earning Date
- SLND 08-11-2025
- CGEN 08-05-2025
- Dividend Yield
- SLND N/A
- CGEN N/A
- EPS Growth
- SLND N/A
- CGEN N/A
- EPS
- SLND N/A
- CGEN N/A
- Revenue
- SLND $931,568,000.00
- CGEN $27,589,000.00
- Revenue This Year
- SLND $3.76
- CGEN N/A
- Revenue Next Year
- SLND $1.08
- CGEN $173.80
- P/E Ratio
- SLND N/A
- CGEN N/A
- Revenue Growth
- SLND N/A
- CGEN N/A
- 52 Week Low
- SLND $1.85
- CGEN $1.13
- 52 Week High
- SLND $4.67
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- SLND 71.29
- CGEN 58.50
- Support Level
- SLND $3.66
- CGEN $1.62
- Resistance Level
- SLND $4.62
- CGEN $1.81
- Average True Range (ATR)
- SLND 0.26
- CGEN 0.08
- MACD
- SLND 0.05
- CGEN -0.00
- Stochastic Oscillator
- SLND 87.04
- CGEN 69.57
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.